Page 51 - GTM-3-1

Global Translational Medicine Personalized, multi-omics disease detection

relocalization. Mol Cell. 2019;73(1):166-182.e7. 30. Mundt F, Albrechtsen NJW, Mann SP, et al. Foresight in
clinical proteomics: current status, ethical considerations,
doi: 10.1016/j.molcel.2018.11.035
and future perspectives. Open Res Eur. 2023;3:59.
20. Lehtio J, Arslan T, Siavelis I, et al. Proteogenomics of non- doi: 10.12688/openreseurope.15810.1
small cell lung cancer reveals molecular subtypes associated
with specific therapeutic targets and immune evasion 31. Mertins P, Tang LC, Krug K, et al. Reproducible workflow
mechanisms. Nat Cancer. 2021;2(11):1224-1242. for multiplexed deep-scale proteome and phosphoproteome
analysis of tumor tissues by liquid chromatography-mass
doi: 10.1038/s43018-021-00259-9 spectrometry. Nat Protoc. 2018;13(7):1632-1661.
21. Clish CB. Metabolomics: An emerging but powerful tool doi: 10.1038/s41596-018-0006-9
for precision medicine. Cold Spring Harb Mol Case Stud.
2015;1(1):a000588. 32. Candia J, Daya GN, Tanaka T, Ferrucci L, Walker KA.
Assessment of variability in the plasma 7k SomaScan
doi: 10.1101/mcs.a000588 proteomics assay. Sci Rep. 2022;12(1):17147.
22. Lu Z, Priya Rajan SA, Song Q, et al. 3D scaffold-free doi: 10.1038/s41598-022-22116-0
microlivers with drug metabolic function generated by
lineage-reprogrammed hepatocytes from human fibroblasts. 33. Huang T, Wang J, Stukalov A, et al. Protein coronas on
Biomaterials. 2021;269:120668. functionalized nanoparticles enable quantitative and precise
large-scale deep plasma proteomics. bioRxiv [Preprint]. 2023.
doi: 10.1016/j.biomaterials.2021.120668
doi: 10.1101/2023.08.28.555225
23. Triozzi PL, Stirling ER, Song Q, et al. Circulating immune
bioenergetic, metabolic, and genetic signatures predict 34. Mund A, Coscia F, Kriston A, et al. Deep visual proteomics
melanoma patients’ response to Anti-PD-1 immune defines single-cell identity and heterogeneity. Nat Biotechnol.
checkpoint blockade. Clin Cancer Res. 2022;28(6):1192-1202. 2022;40(8):1231-1240.
doi: 10.1038/s41587-022-01302-5
doi: 10.1158/1078-0432.CCR-21-3114
35. Eckert MA, Coscia F, Chryplewicz A, et al. Proteomics
24. Ravindra KC, Vaidya VS, Wang Z, et al. Tandem mass tag-
based quantitative proteomic profiling identifies candidate reveals NNMT as a master metabolic regulator of cancer-
serum biomarkers of drug-induced liver injury in humans. associated fibroblasts. Nature. 2019;569(7758):723-728.
Nat Commun. 2023;14(1):1215. doi: 10.1038/s41586-019-1173-8

doi: 10.1038/s41467-023-36858-6 36. Zhuang YJ, Mangwiro Y, Wake M, Saffery R, Greaves RF.
Multi-omics analysis from archival neonatal dried blood
25. Niu L, Thiele M, Geyer PE, et al. Noninvasive proteomic spots: Limitations and opportunities. Clin Chem Lab Med.
biomarkers for alcohol-related liver disease. Nat Med. 2022;60(9):1318-1341.
2022;28(6):1277-1287.
doi: 10.1515/cclm-2022-0311
doi: 10.1038/s41591-022-01850-y
37. Omenn GS, Lane L, Overall CM, et al. The 2022 Report on
26. Eldjarn GH, Ferkingstad E, Lund SH, et al. Large-scale the human proteome from the HUPO human proteome
plasma proteomics comparisons through genetics and project. J Proteome Res. 2023;22(4):1024-1042.
disease associations. Nature. 2023;622(7982):348-358.
doi: 10.1021/acs.jproteome.2c00498
doi: 10.1038/s41586-023-06563-x
38. Webel H, Niu L, Nielsen BA, et al. Imputation of label-free
27. Sun BB, Chiou J, Traylor M, et al. Plasma proteomic quantitative mass spectrometry-based proteomics data using
associations with genetics and health in the UK Biobank. self supervised deep learning. bioRxiv [Preprint]. 2023.
Nature. 2023;622(7982):329-338.
doi: 10.1101/2023.01.12.523792
doi: 10.1038/s41586-023-06592-6
39. Liu J, Yang M, Yu Y, Xu H, Li K, Zhou X. Large language
28. Dhindsa RS, Burren OS, Sun BB, et al. Rare variant models in bioinformatics: applications and perspectives.
associations with plasma protein levels in the UK Biobank. ArXiv [Preprint]. 2024.
Nature. 2023;622(7982):339-347.
40. Mani DR, Krug K, Zhang B, et al. Cancer proteogenomics:
doi: 10.1038/s41586-023-06547-x current impact and future prospects. Nat Rev Cancer.
29. Sanyal AJ, Williams SA, Lavine JE, et al. Defining the serum 2022;22(5):298-313.
proteomic signature of hepatic steatosis, inflammation, doi: 10.1038/s41568-022-00446-5
ballooning and fibrosis in non-alcoholic fatty liver disease. 41. Santos A, Colaço AR, Nielsen AB, et al. A knowledge
J Hepatol. 2023;78(4):693-703.
graph to interpret clinical proteomics data. Nat Biotechnol.
doi: 10.1016/j.jhep.2022.11.029 2022;40(5):692-702.

Volume 3 Issue 1 (2024) 11 https://doi.org/10.36922/gtm.2357